Selfcare purchases majority stake in Orgenics:
This article was originally published in Clinica
US diagnostics manufacturer Selfcare has acquired 57% of Israeli company Orgenics for $7 million in cash and the conversion of a $1 million debenture. Selfcare announced its intention to purchase Orgenics in its IPO prospectus in June (see Clinica No 713, p 13). It plans to purchase the rest of Orgenics before August 1997.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.